Abstract
HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtricitabine is an effective means of decreasing human immunodeficiency virus (HIV) acquisition among women. However, few women are prescribed and are taking PrEP. This article offers perspectives on barriers to use and strategies to increase uptake among women.
Funding Information
  • National Institutes of Health (K23MH107316)
  • Harvard University Center for AIDS Research (P30AI060354)

This publication has 19 references indexed in Scilit: